Get started
Work

Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476)

Year: 2017
Type: article
DOI: 10.1093/annonc/mdx440.027
Authors: N. James, J. de Bono, M.R. Spears, N.W. Clarke, M.D. Mason, D. Dearnaley, A.W.S. Ritchie, M. Russell, C. Gilson, R. Jones, S. Gillessen, D. Matheson, S. Aung, A. Birtle, S. Chowdhury, J. Gale, Z. Malik, J. O'Sullivan, M.K. Parmar, M.R. Sydes
Institutions: University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Institute of Cancer Research, Royal Marsden Hospital, MRC Clinical Trials Unit at UCL, Medical Research Council, Salford Royal NHS Foundation Trust, Cardiff University, Gloucestershire Royal Hospital, University of Glasgow, University College London, Kantonsspital St. Gallen, Royal Devon & Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital, Royal Preston Hospital, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Queen Alexandra Hospital, Clatterbridge Cancer Centre NHS Foundation Trust, Queen's University Belfast
Language: English
Field: Medicine
Open Access status: bronze
Funders: Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Exelixis, Clovis Oncology, National Institute for Health and Care Research, Astellas Pharma, Genentech, Medical Research Council, Economic and Social Research Council
OpenAlex ID: W2763103404
FWCI: 0.681
Cites:
Cited by: 9
Related to: 10